Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is a Healthcare company (Biotechnology) with a market capitalization of $191M. The Maz Rating grades it against the other companies in its sector.
Artiva Biotherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.86, Artiva Biotherapeutics, Inc. trades at 0.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -45.3%, return on invested capital of -31.9% and a free cash flow yield of -56.5%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 19.88. Over the past 52 weeks the share price ranged from $2.96 to $14.53, with a beta of 2.41.
Artiva Biotherapeutics, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 2 Buy and 3 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Artiva Biotherapeutics, Inc. (ARTV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 104.4% / 30% · Interest income / Revenue 314100000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 104.4% / 33% · Receivables / Mkt Cap (36m) 0.56% / 49% · Interest income / Revenue 314100000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 104.4% / 33.33% · Receivables / Mkt Cap (24m) 0.56% / 33.33% · Interest income / Revenue 314100000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.24% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 91.0% / 33.33% · Receivables / Avg Assets (4Q) 0.34% / 33.33% · Interest income / Revenue 314100000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 93.0% / 33.33% · (Cash+Recv) / Total Assets 93.5% / 33.33% · Interest income / Revenue 314100000.0% / 5% | Fail |
No. As of September 2026, Artiva Biotherapeutics, Inc. (ARTV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Artiva Biotherapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 314100000.0% of each dividend: Artiva Biotherapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.